ALX Oncology Holdings Inc (NAS:ALXO)
$ 8.21 -0.23 (-2.73%) Market Cap: 427.74 Mil Enterprise Value: 291.47 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 33/100

ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat Transcript

Mar 09, 2021 / 12:00PM GMT
Release Date Price: $73.54 (+5.68%)
Swayampakula Ramakanth
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Good day, and thanks for joining us to have a conversation with Jaume Pons, CEO; and Sophia Randolph, CMO of ALX Oncology. ALX Oncology is developing novel antibodies targeting the CD47-SIRPalpha axis. This -- their lead asset, ALX148, is being tested in the clinic as a therapy for treating solid tumors, a first for anti-CD47 therapies.

To discuss the clinical development to date, the expected progress in 2021 and beyond, I welcome Jaume and Sophia to this fireside chat. Jaume and Sophia, glad to see you both and accepting our invitation to talk to our audience today.

Jaume Pons
ALX Oncology Holdings Inc. - President, CEO & Director

Thank you.

Sophia Randolph
ALX Oncology Holdings Inc. - Chief Medical Officer

Thank you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot